Medical Oncology

Journal Club ft. Lancet publication

Questions discussed in this category

Does it matter whether one uses MSI PCR testing versus IHC for MMR deficiency testing in order to determine eligibility for immunotherapy?

4 Answers available

How do CheckMate 8HW results impact your sequencing of available therapies in dMMR/MSI-H metastatic colorectal cancer?

Will you now uniformly start with nivo/ipi > chemotherapy? If so, would you ever reintroduce another checkpoint monotherapy down the line? Or do yo...

3 Answers available

For a patient with metastatic colon cancer which is MSI-H/dMMR and BRAF V600E+, what would be your preferred first line treatment?

In the setting of CM-8HW and BREAKWATER results, how do you prioritize?

3 Answers available

Are there long-term toxicity and QOL considerations for patients receiving nivo/ipi compared to checkpoint monotherapy that would impact your treatment decisions for first line metastatic MSI-H/dMMR CRC?

2 Answers available

Of the two ipilimumab dosing schedules utilized with nivolumab on CheckMate 8HW, do you have a preference in your own practice?

The primary nivo/ipi arm was q3 wks x4c, whereas the post-chemo crossover arm used q6 wks until progression. Is one schedule clearly more effective or...

2 Answers available

What factors do you consider when deciding between dual vs single-agent immunotherapy for patients with MSI-H or dMMR metastatic CRC?

Is there any data comparing Nivo/Ipi Vs Pembro or Dostarlimab? Can this be extrapolated from the CM-8HW Nivo/Ipi vs Nivo arm?

2 Answers available

Papers discussed in this category

Journal of translational medicine, 2024 Feb 13

Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017-05-01

Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology.

The Journal of molecular diagnostics : JMD, 2011-05

Quality assessment and correlation of microsatellite instability and immunohistochemical markers among population- and clinic-based colorectal tumors results from the Colon Cancer Family Registry.

Lancet (London, England), 2025 Jan 23

Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018-03-10

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer.

N Engl J Med,

Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.

J Clin Oncol, 2021 Oct 12

First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study.

Nature medicine, 2025 Jan 25

Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial.

The Lancet. Oncology, 2017-09

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.

The American journal of pathology, 2001-12

Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019 Nov 14

Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164.

European journal of cancer (Oxford, England : 1990), 2017 Oct 19

Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency.

Journal of the National Cancer Institute, 2018 Sep 01

The Heterogeneity Between Lynch-Associated and Sporadic MMR Deficiency in Colorectal Cancers.

Frontiers in immunology, 2020 Jan 09

Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer.

Cureus, 2025 Jan 02

Triple M Overlap Syndrome: Myocarditis, Myositis and Myasthenia Gravis After a Single Administration of Pembrolizumab.

The Lancet. Oncology, 2022 Apr 12

Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study.

The New England journal of medicine, 2024 Nov 28

Nivolumab plus Ipilimumab in Microsatellite-Instability-High Metastatic Colorectal Cancer.

Related Topics in Medical Oncology